Institute for Clinical & Economic Review Publishes Final Evidence Report, Policy Recommendations on Tirzepatide for Type 2 Diabetes
February 16, 2022
February 16, 2022
BOSTON, Massachusetts, Feb. 16 (TNSRep) -- The Institute for Clinical and Economic Review issued the following news release on Feb. 15, 2022:
* * *
Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added to background therapy in individuals with type 2 diabetes --
Tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 - $5,700 per year --
Payer . . .
* * *
Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added to background therapy in individuals with type 2 diabetes --
Tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 - $5,700 per year --
Payer . . .